AbCellera Biologics Inc.
ABCL
$2.32
-$0.075-3.14%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 33.06% | -38.39% | 9.06% | 13.87% | -64.80% |
| Total Depreciation and Amortization | -147.26% | 0.68% | 462.18% | -25.72% | 22.95% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 384.39% | 55.11% | -220.52% | 12.31% | 22.13% |
| Change in Net Operating Assets | 360.10% | 28.70% | 70.22% | -2,014.83% | -80.32% |
| Cash from Operations | 72.30% | 3.62% | 28.15% | -112.68% | -18,400.94% |
| Capital Expenditure | 15.59% | 7.93% | 16.69% | -67.28% | 29.02% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 131.08% | -69.24% | 33.59% | 646.40% | -231.11% |
| Cash from Investing | 865.47% | -92.90% | 74.18% | 222.97% | -90.23% |
| Total Debt Issued | 90.17% | 30.72% | 11.72% | -57.77% | -23.32% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -50.76% | -48.32% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 3.80% | -0.55% | 1.08% | 0.00% | 0.54% |
| Cash from Financing | 31.70% | 18.63% | -6.36% | -24.81% | -43.21% |
| Foreign Exchange rate Adjustments | -688.56% | 953.49% | 94.49% | -173.13% | 200.47% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 236.97% | -187.60% | 353.80% | 75.07% | -433.80% |
